The panel features founders of three biotech companies (Algen, Gnosis Bio, Tessera) built on Nobel Prize-winning science, operating at the intersection of AI and genetic medicine.
These companies are pioneering next-generation platforms for gene regulation (Algen), targeted gene silencing (Gnosis), and gene writing (Tessera) to improve drug development efficiency and tackle previously 'undruggable' diseases.
AI is presented as a transformative force, enabling the rapid analysis of vast biological data to accelerate discovery, increase clinical success rates, and lower costs.
Panelists predict a future of preventative genetic therapies and a dramatic reduction in drug failure rates, but warn that US biotech leadership is threatened by China's strategic investment and more agile regulatory environment.
9 quotes
Concerns Raised
The US biotech industry risks losing its competitive edge to China due to disparities in government investment and regulatory hurdles.
The traditional pharmaceutical R&D model is inefficient, with a 90-95% failure rate that new technologies aim to solve.
The vast majority (90-95%) of human gene functions remain unknown, representing a major frontier for biological discovery.
Opportunities Identified
Developing preventative genetic injections that act like 'vaccines' against chronic diseases like Alzheimer's and cardiovascular disease.
Eliminating the concept of 'undruggable' targets by using AI to design precision medicines for any disease pathway.
Dramatically improving the overall drug failure rate in the pharmaceutical industry from 90% to 80% within five years.
Leveraging large-scale pharma partnerships to fund R&D and scale platform technologies for broad application.